Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series
- PMID: 35317070
- PMCID: PMC8922540
- DOI: 10.1002/ccr3.5573
Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series
Abstract
Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.
Keywords: atypical hemolytic uremic syndrome; complement; eculizumab; nephrology; thrombotic microangiopathy.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
None.
References
-
- Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic‐uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4‐21. - PubMed
-
- Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: review of clinical presentation, diagnosis and management. J Immunol Methods. 2018;461:15‐22. - PubMed
-
- Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15‐39. - PubMed
-
- Fakhouri F, Zuber J, Frémeaux‐Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681‐696. - PubMed
Publication types
LinkOut - more resources
Full Text Sources